Study points to potential new use for Viagra
Led by professor of Pharmacology and Toxicology Donald Maurice, the study focuses on the effects of Viagra – the popular erectile dysfunction drug, which is also used to treat pulmonary hypertension.
The team’s findings will be published on-line this week in the international journal Proceedings of the National Academy of Sciences (PNAS).
“As scientists, we’re excited about this discovery because it’s a fundamentally new approach to regulating what enzymes do in cells,” says Dr. Maurice, a Career Scientist with the Ontario Heart and Stroke Foundation. “The fact that it also offers a potentially novel use of a drug already widely in use for other applications is an unexpected bonus.”
The enzyme targeted by the Queen’s researchers is known to regulate the activity of platelets: small blood cells needed for normal blood clotting. Problems can arise when people have stents permanently implanted in their arteries to maintain blood flow. Their platelets sometimes bind to the stent and, if enough platelets accumulate to form a blockage, this may cause a sudden, massive heart attack or stroke to occur.
Drugs like Viagra have been shown to inhibit PDE5, explains Lindsay Wilson, a PhD student in Pathology and Molecular Medicine and first author on the study. Until now, however, it hasn’t been possible to isolate the small “pool” of activity within the cell where this is occurring.
The Queen’s study shows that within each cell there are two different pools of the PDE5 enzyme, but that only one of them regulates platelet activation. “Understanding how the cell works should allow us to affect the activity of enzymes in one neighborhood – and leave alone their ‘identical twins’ in a different neighborhood in that cell,” says Ms Wilson.
“The idea is to use a PDE5 inhibitor such as Viagra selectively to inhibit platelet function,” she continues. We now know that not all the enzymes in the cell are doing the same job. Just like in real estate, it’s all about the location!”
Other members of the Queen’s research team are Hisham Elbatarny and Brian Bennett (Pharmacology and Toxicology), and Scott Crawley (Biochemistry). Funding came from the Ontario Heart and Stroke Foundation and the Canadian Institutes of Health Research (CIHR).
PLEASE NOTE: A PDF copy of the study is available upon request.
Nancy Dorrance, nancy.dorrance@queensu.ca, 613.533.2869 or Molly Kehoe, molly.kehoe@queensu.ca, 613.533.2877, Queen's News & Media Services.
Media Contact
More Information:
http://www.queensu.caAll latest news from the category: Studies and Analyses
innovations-report maintains a wealth of in-depth studies and analyses from a variety of subject areas including business and finance, medicine and pharmacology, ecology and the environment, energy, communications and media, transportation, work, family and leisure.
Newest articles
New molecular sensor tracks energy use at the subcellular level
A molecule called adenosine triphosphate (ATP) is the basic unit of biochemical energy that fuels the activities of all cells. Now a team led by researchers at Weill Cornell Medicine…
Researchers discover new pathway to cancer cell suicide
The way cancer cells die from chemotherapy appears to be different than previously understood. Chemotherapy kills cancer cells. But the way these cells die appears to be different than previously…
‘Vigorous melting’ at Antarctica’s Thwaites Glacier
Satellite radar data show kilometer-scale seawater intrusion, causing ice to rise and fall. A team of glaciologists led by researchers at the University of California, Irvine used high-resolution satellite radar…
